09.11.2011 • NewsBASFgenetically modifiedAmflora

BASF Applies for EU Approval for Fortuna GM Potato

BASF has applied for European Union approval for Fortuna, a potato genetically modified to resist a common plant disease, as the German chemicals company tries again to overcome resistance in the region to GM food.

The world's largest chemical maker by sales said on Monday it had asked for clearance for Fortuna, covering commercial cultivation and consumption by humans and animals.

In March 2010, BASF won European Commission approval for Amflora, another genetically modified potato, for commercial cultivation, marking the bloc's first GM cultivation approval in 12 years.

While Amflora was designed for industrial-starch production, Fortuna marks the first GM food plant BASF has sought to market in Europe, where consumers' opposition to such products remains widespread.

BASF said it expected market introduction in 2014 or 2015, even though it took BASF about 14 years to win clearance for Amflora. EU rules on the GM plant approval process have been streamlined since then, a company spokesman said.

The chemical maker is not publishing an annual peak sales assessment for the product for now, he added.

The company said its researchers made Fortuna resistant to late blight, the world's most damaging potato disease, which is caused by Phytophthora infestans, a fungi-like pathogen.

The plant disease, which was behind the mass starvation that ravaged Ireland in the 1840s, is cited by BASF as still causing the loss of up to 20% of the global potato harvest per year.  

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.